<DOC>
	<DOCNO>NCT00003644</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether receive combine carboplatin paclitaxel plus continued low-dose paclitaxel effective carboplatin paclitaxel alone early-stage ovarian cancer . PURPOSE : This randomized phase III trial study carboplatin paclitaxel alone see well work compare carboplatin paclitaxel together continue low-dose paclitaxel treat patient early-stage ovarian cancer .</brief_summary>
	<brief_title>Carboplatin Plus Paclitaxel With Without Continued Low-Dose Paclitaxel Treating Patients With Early-Stage Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free interval overall survival patient early stage ovarian epithelial cancer treat carboplatin paclitaxel without low-dose paclitaxel . - Assess frequency severity toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute . Treatment repeat every 21 day 3 course . Four week completion paclitaxel carboplatin , patient receive low-dose paclitaxel IV 1 hour week 24 week . - Arm II : Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute . Treatment repeat every 21 day 3 course . Patients undergo observation . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 500 patient accrue study within 5.5 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial cancer one follow histologic cell type : Serous adenocarcinoma Malignant Brenner 's tumor Mucinous adenocarcinoma Endometrioid Adenocarcinoma Clear cell adenocarcinoma Undifferentiated carcinoma Transitional cell Mixed epithelial carcinoma Adenocarcinoma otherwise specify Meets 1 follow criterion : Stage Ia Ib , grade 3 clear cell Stage Ic II , grades/histologies Complete surgical staging No tumor low malignant potential ( borderline tumor ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 03 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time normal Alkaline phosphatase great 3 time normal SGOT great 3 time normal Renal : Creatinine great 2.0 mg/dL Other : No invasive malignancy within past 5 year except nonmelanoma skin cancer No major systemic medical illness expect affect survival Body surface area great 2.0 PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No prior treatment malignancy except surgical staging No prior anticancer therapy would preclude study participation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>